Phase
Condition
Thrombosis
Dysfunctional Uterine Bleeding
Platelet Disorders
Treatment
Avatrombopag
Clinical Study ID
Ages 6-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age 6-18 years old (including both ends), male and female;
Diagnosed with primary immune thrombocytopenia (ITP);
Patients who had previously received eltrombopag treatment and then converted toavatrombopag treatment because of ineffectiveness (platelet count < 30×10^9/L aftereltrombopag treatment, or platelet count increased less than 2 times of the basicvalue, or bleeding) or large platelet fluctuation or due to patient preference,economic reasons and other reasons;
Cardiac function of the New York Society of Cardiac Function ≤ 2;
Understand the study procedure and voluntarily sign the informed consent.
Exclusion
Exclusion Criteria:
Secondary thrombocytopenia caused by various reasons, such as connective tissuedisorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome,malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency,lymphoma, etc.;
Subjects with primary disease of important organs (liver, kidney, heart, etc.), orwith immune system diseases;
Subjects who are known to be allergic to avatrombopag or any of its excipients;
Subjects who had used rituximab within the last 3 months;
Subjects who underwent splenectomy within the last 3 months;
Subjects with a history of abnormal platelet aggregation that may affect thereliability of platelet count measurements;
Any medical history or condition that the investigator deems unsuitable forparticipation in the study.
Study Design
Study Description
Connect with a study center
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin,
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.